Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5…
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of…
PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of…
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy…
PharmAla will be the initial supplier for clinical materials in a series of Psychedelic therapy…
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting…
NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting…
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions…
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
First-ever orphan drug designation for genetically modified gamma-delta T cell therapies This orphan drug designation…
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
New role supports the Company’s objective to lead the industry with faster, more inclusive clinical…
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical…
WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…